AbbVie’s (ABBV) “Buy” Rating Reiterated at Guggenheim
AbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “buy” rating restated by Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have a $214.00 price objective on the stock. Guggenheim’s price objective would suggest a potential upside of 23.86% from the stock’s current price. A number of other research firms […]
More Stories
Semrush vs Serpstat vs Ahrefs: Which Is Better?
No business today can skip search engine optimization if they want to lead in the online marketplace. From keyword research...
Murder in a Small Town Season 3 Is Releasing Soon on Netflix
Murder in a Small Town Season 3 is coming back with an-all-new drama and suspenseful storyline for its viewers. The...
Netflix’s Fauda Season 5: Release Date, Cast Members, Plot, and Episodes
Fauda season 5 is coming to Netflix soon! Your years of waiting are finally over. Are you also one of...
How to Cancel Hulu Subscriptions? A Complete Guide For Beginners
Worried about your money being deducted? Do you also have a subscription and now don’t know how to cancel your...
Dolly Parton, queen of country music, dies at 80
By Reuters Aug 25 (Reuters) – Dolly Parton was around six when she wrote her first song: “Little Tiny Tasseltop,”...
Canada’s Dollar-for-Dollar Tariff Response Exposes a Trade Relationship America Should Have Reexamined Decades Ago
By Stephen Zogopoulos, USNN World News Canada has now formally answered Washington’s latest tariffs with what it calls a “dollar-for-dollar,...